Loading insider details...
Beta
Latest Form 4 (Sep 1, 2026): Disposition to Issuer of 7,956 CRNX shares, $676.3K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to Issuer | 7,956 | $676.3K |
| Aug 24, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/Award | 471 | n/a |
| Mar 4, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale | 6,713 | $266.3K |
| Feb 25, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/Award | 32,000 | n/a |
| Mar 11, 2025 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/Award | 52,000 | n/a |
| Jul 2, 2024 | Revance Therapeutics, Inc. (RVNC) | Grant/Award | 1,000 | $2.2K |
| Mar 19, 2024 | Revance Therapeutics, Inc. (RVNC) | Tax Withholding | 3,822 | $20.3K |
| Mar 4, 2024 | Revance Therapeutics, Inc. (RVNC) | Grant/Award | 17,447 | n/a |
| Feb 2, 2024 | Revance Therapeutics, Inc. (RVNC) | Grant/Award | 96,667 | n/a |